Abnormalities in fibrinolysis at the time of admission are associated with deep vein thrombosis, mortality and disability in pediatric trauma population

2017 ◽  
Vol 52 (4) ◽  
pp. 595-596
Author(s):  
Brittany Catanach
1980 ◽  
Vol 44 (03) ◽  
pp. 135-137 ◽  
Author(s):  
Thorkild Lund Andreasen

SummaryAntithrombin III (At-III) was measured at the time of admission and two days later in 131 patients laid up in a coronary care unit. The patients were examined for deep-vein thrombosis (DVT) clinically and by means of 125I-fibrinogen scanning. 19 patients developed DVT. In 11 subjects with and 25 without DVT At-III decreased more than 10%. And in 7 with and 17 without DVT At-III decreased more than 15%. One person with DVT had subnormal At-III. By using decrease of At-III or subnormal initial At-III to predict DVT the following predictive value (PV) were found. Decrease ≤ 10%, PV pos.= 0.32 and PV neg. = 0.93. Decrease ≤ 15%, PV pos. = 0.32 and PV neg. = 0.90. The positive predictive values obtained were too low to let decreasing At-III give occasion for prophylactic anticoagulant treatment.


CHEST Journal ◽  
2007 ◽  
Vol 132 (4) ◽  
pp. 625C
Author(s):  
Hani Jaouni ◽  
Shadi Haddadin ◽  
Lenora Adams ◽  
Joshua S. Botdorf ◽  
Maen B. Nusair ◽  
...  

1996 ◽  
Vol 172 (1) ◽  
pp. 13-14 ◽  
Author(s):  
L.D. Britt ◽  
David Zolfaghari ◽  
Elizabeth Kennedy ◽  
Keith J. Pagel ◽  
Anita Minghini

2015 ◽  
Vol 199 (2) ◽  
pp. 545-551 ◽  
Author(s):  
Christopher P. Michetti ◽  
Elizabeth Franco ◽  
Jonathan Coleman ◽  
Anna Bradford ◽  
Amber W. Trickey

2019 ◽  
pp. 36-43
Author(s):  
E. A. Shcheglov ◽  
N. N. Alontseva ◽  
P. S. Guliaeva

The aim of this study was to assess the risk of use of rivaroxaban, which was associated with gastro-duodenal bleeding in patients with deep venous thrombosis. Methods: an analysis of anticoagulant treatment in 683 patients with deep venous phlebothrombosis. All the patients underwent fiberoptic gastroduodenoscopic procedure prior to the anticoagulant treatment. When erosive-ulcerative lesions were detected, the patients received antisecretory therapy with proton pump inhibitors along with anticoagulant therapy. Results: EGD did not show any only stomach pathology only in 10.7 percent of patients at the time of admission. A symptom-free pathology that became a diagnostic finding was identified in 53.1 percent of patients. Fiberoptic gastroduodenoscopy showed completed bleeding or bleeding that was stopped using endoscopic balloon tamponade with achievement of stable hemostasis in 12.9 patients. 59.1 percent of patients received anti-coagulant therapy with rivaroxaban (Xarelto®). In the presented series of patients with acute deep vein thrombosis, the use of rivopoxaban appeared a safe therapeutic option not only in patients with erosive-ulcerative lesions in the gastroduodenal system, but also in those with endoscopic signs of stopped bleeding (on the top of already administered antisecretory therapy with proton pump inhibitors).


Sign in / Sign up

Export Citation Format

Share Document